J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells

P. R. Taylor, G. K. Koski, C. C. Paustian, E. Bailey, P. A. Cohen, F. B.G. Moore, D. H. Zimmerman, K. S. Rosenthal

Research output: Contribution to journalArticle

Abstract

The Ligand Epitope Antigen Presentation System (LEAPS) converts a peptide containing a T cell epitope as small as 8 amino acids into an immunogen and directs the nature of the subsequent response. Tandem synthesis of the J peptide (a peptide from the beta-2-microglobulin) with peptides of 15 or 30 amino acids from HSV-1 or HIV made them immunogenic and promoted Th1 immune responses. Immunization of A/J or C57BL/6 mice with J-LEAPS heteroconjugates containing an epitope from the HSV-1 glycoprotein D (JgD) or an epitope from the HIV gag protein (JH) emulsified with Seppic ISA51 induced increased levels of IL-12p70 by day 3 and increased levels of interferon gamma (IFN-gamma) on days 10 and 24. Interestingly, levels of IL-10, TNF-alpha, and IL-6 did not change. Neither the H nor the gD peptides alone elicited responses and only weak responses followed immunization with the J peptide. Bone marrow (BM) cells became CD86 and CD11c positive within 48. h of treatment with JgD or JH. JH or JgD treatment promoted IL-12p70 production and expression of CD8 denoting the maturation and activation of a subclass of myeloid DCs. Pure cultures of immature myeloid DCs also responded to JgD treatment, forming clusters, developing dendrites, and producing IL-12p70 within 24. h. The JH or JgD treated bone marrow cells (JgD-DC) were necessary and sufficient to activate splenic T cells to produce IFN-gamma and the JgD-DC provided an antigen specific booster response to T cells from JgD immunized mice. Adoptive transfer of JgD-DC was also sufficient to initiate protective antigen specific immunity from lethal challenge with HSV-1. The J-LEAPS vaccines appear to act as an adjuvant and immunogen on DC precursors in a unique manner to promote activation and maturation into IL-12p70 producing DCs which then can initiate sufficient Th1 immune responses to elicit protection without production of acute phase cytokines.

Original languageEnglish (US)
Pages (from-to)5533-5542
Number of pages10
JournalVaccine
Volume28
Issue number34
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

antigen presentation
Antigen Presentation
dendritic cells
Dendritic Cells
epitopes
Epitopes
Vaccines
peptides
vaccines
Ligands
Peptides
mice
Human Herpesvirus 1
antigens
T-lymphocytes
bone marrow cells
interferon-gamma
Bone Marrow Cells
Interferon-gamma
Immunization

Keywords

  • Adoptive transfer
  • Dendritic cells
  • HIV
  • HSV
  • IL12
  • LEAPS
  • Th1
  • Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Taylor, P. R., Koski, G. K., Paustian, C. C., Bailey, E., Cohen, P. A., Moore, F. B. G., ... Rosenthal, K. S. (2010). J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine, 28(34), 5533-5542. https://doi.org/10.1016/j.vaccine.2010.06.043

J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. / Taylor, P. R.; Koski, G. K.; Paustian, C. C.; Bailey, E.; Cohen, P. A.; Moore, F. B.G.; Zimmerman, D. H.; Rosenthal, K. S.

In: Vaccine, Vol. 28, No. 34, 01.08.2010, p. 5533-5542.

Research output: Contribution to journalArticle

Taylor, PR, Koski, GK, Paustian, CC, Bailey, E, Cohen, PA, Moore, FBG, Zimmerman, DH & Rosenthal, KS 2010, 'J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells', Vaccine, vol. 28, no. 34, pp. 5533-5542. https://doi.org/10.1016/j.vaccine.2010.06.043
Taylor PR, Koski GK, Paustian CC, Bailey E, Cohen PA, Moore FBG et al. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine. 2010 Aug 1;28(34):5533-5542. https://doi.org/10.1016/j.vaccine.2010.06.043
Taylor, P. R. ; Koski, G. K. ; Paustian, C. C. ; Bailey, E. ; Cohen, P. A. ; Moore, F. B.G. ; Zimmerman, D. H. ; Rosenthal, K. S. / J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. In: Vaccine. 2010 ; Vol. 28, No. 34. pp. 5533-5542.
@article{26e057bef84c4227a5cc821ac72b824c,
title = "J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells",
abstract = "The Ligand Epitope Antigen Presentation System (LEAPS) converts a peptide containing a T cell epitope as small as 8 amino acids into an immunogen and directs the nature of the subsequent response. Tandem synthesis of the J peptide (a peptide from the beta-2-microglobulin) with peptides of 15 or 30 amino acids from HSV-1 or HIV made them immunogenic and promoted Th1 immune responses. Immunization of A/J or C57BL/6 mice with J-LEAPS heteroconjugates containing an epitope from the HSV-1 glycoprotein D (JgD) or an epitope from the HIV gag protein (JH) emulsified with Seppic ISA51 induced increased levels of IL-12p70 by day 3 and increased levels of interferon gamma (IFN-gamma) on days 10 and 24. Interestingly, levels of IL-10, TNF-alpha, and IL-6 did not change. Neither the H nor the gD peptides alone elicited responses and only weak responses followed immunization with the J peptide. Bone marrow (BM) cells became CD86 and CD11c positive within 48. h of treatment with JgD or JH. JH or JgD treatment promoted IL-12p70 production and expression of CD8 denoting the maturation and activation of a subclass of myeloid DCs. Pure cultures of immature myeloid DCs also responded to JgD treatment, forming clusters, developing dendrites, and producing IL-12p70 within 24. h. The JH or JgD treated bone marrow cells (JgD-DC) were necessary and sufficient to activate splenic T cells to produce IFN-gamma and the JgD-DC provided an antigen specific booster response to T cells from JgD immunized mice. Adoptive transfer of JgD-DC was also sufficient to initiate protective antigen specific immunity from lethal challenge with HSV-1. The J-LEAPS vaccines appear to act as an adjuvant and immunogen on DC precursors in a unique manner to promote activation and maturation into IL-12p70 producing DCs which then can initiate sufficient Th1 immune responses to elicit protection without production of acute phase cytokines.",
keywords = "Adoptive transfer, Dendritic cells, HIV, HSV, IL12, LEAPS, Th1, Vaccines",
author = "Taylor, {P. R.} and Koski, {G. K.} and Paustian, {C. C.} and E. Bailey and Cohen, {P. A.} and Moore, {F. B.G.} and Zimmerman, {D. H.} and Rosenthal, {K. S.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1016/j.vaccine.2010.06.043",
language = "English (US)",
volume = "28",
pages = "5533--5542",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "34",

}

TY - JOUR

T1 - J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells

AU - Taylor, P. R.

AU - Koski, G. K.

AU - Paustian, C. C.

AU - Bailey, E.

AU - Cohen, P. A.

AU - Moore, F. B.G.

AU - Zimmerman, D. H.

AU - Rosenthal, K. S.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - The Ligand Epitope Antigen Presentation System (LEAPS) converts a peptide containing a T cell epitope as small as 8 amino acids into an immunogen and directs the nature of the subsequent response. Tandem synthesis of the J peptide (a peptide from the beta-2-microglobulin) with peptides of 15 or 30 amino acids from HSV-1 or HIV made them immunogenic and promoted Th1 immune responses. Immunization of A/J or C57BL/6 mice with J-LEAPS heteroconjugates containing an epitope from the HSV-1 glycoprotein D (JgD) or an epitope from the HIV gag protein (JH) emulsified with Seppic ISA51 induced increased levels of IL-12p70 by day 3 and increased levels of interferon gamma (IFN-gamma) on days 10 and 24. Interestingly, levels of IL-10, TNF-alpha, and IL-6 did not change. Neither the H nor the gD peptides alone elicited responses and only weak responses followed immunization with the J peptide. Bone marrow (BM) cells became CD86 and CD11c positive within 48. h of treatment with JgD or JH. JH or JgD treatment promoted IL-12p70 production and expression of CD8 denoting the maturation and activation of a subclass of myeloid DCs. Pure cultures of immature myeloid DCs also responded to JgD treatment, forming clusters, developing dendrites, and producing IL-12p70 within 24. h. The JH or JgD treated bone marrow cells (JgD-DC) were necessary and sufficient to activate splenic T cells to produce IFN-gamma and the JgD-DC provided an antigen specific booster response to T cells from JgD immunized mice. Adoptive transfer of JgD-DC was also sufficient to initiate protective antigen specific immunity from lethal challenge with HSV-1. The J-LEAPS vaccines appear to act as an adjuvant and immunogen on DC precursors in a unique manner to promote activation and maturation into IL-12p70 producing DCs which then can initiate sufficient Th1 immune responses to elicit protection without production of acute phase cytokines.

AB - The Ligand Epitope Antigen Presentation System (LEAPS) converts a peptide containing a T cell epitope as small as 8 amino acids into an immunogen and directs the nature of the subsequent response. Tandem synthesis of the J peptide (a peptide from the beta-2-microglobulin) with peptides of 15 or 30 amino acids from HSV-1 or HIV made them immunogenic and promoted Th1 immune responses. Immunization of A/J or C57BL/6 mice with J-LEAPS heteroconjugates containing an epitope from the HSV-1 glycoprotein D (JgD) or an epitope from the HIV gag protein (JH) emulsified with Seppic ISA51 induced increased levels of IL-12p70 by day 3 and increased levels of interferon gamma (IFN-gamma) on days 10 and 24. Interestingly, levels of IL-10, TNF-alpha, and IL-6 did not change. Neither the H nor the gD peptides alone elicited responses and only weak responses followed immunization with the J peptide. Bone marrow (BM) cells became CD86 and CD11c positive within 48. h of treatment with JgD or JH. JH or JgD treatment promoted IL-12p70 production and expression of CD8 denoting the maturation and activation of a subclass of myeloid DCs. Pure cultures of immature myeloid DCs also responded to JgD treatment, forming clusters, developing dendrites, and producing IL-12p70 within 24. h. The JH or JgD treated bone marrow cells (JgD-DC) were necessary and sufficient to activate splenic T cells to produce IFN-gamma and the JgD-DC provided an antigen specific booster response to T cells from JgD immunized mice. Adoptive transfer of JgD-DC was also sufficient to initiate protective antigen specific immunity from lethal challenge with HSV-1. The J-LEAPS vaccines appear to act as an adjuvant and immunogen on DC precursors in a unique manner to promote activation and maturation into IL-12p70 producing DCs which then can initiate sufficient Th1 immune responses to elicit protection without production of acute phase cytokines.

KW - Adoptive transfer

KW - Dendritic cells

KW - HIV

KW - HSV

KW - IL12

KW - LEAPS

KW - Th1

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=77955052320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955052320&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.06.043

DO - 10.1016/j.vaccine.2010.06.043

M3 - Article

C2 - 20600501

AN - SCOPUS:77955052320

VL - 28

SP - 5533

EP - 5542

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 34

ER -